MAP2K7 Loss-of-function

CI-VAR-00002548Explore in graph →CIViC 5567

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Estrogen Receptor-positive Breast Cancer3unmapped disease
MAP2K7 Loss-of-function	(oncogenic)	Oncogenic	D	Supports Oncogenicity	4	submitted	EID13221 MAP2K7 loss promoted metastatic behavior in an ER-positive breast cancer model. CRISPR/Cas9 MAP2K7-knockout MCF-7 cells showed >97% suppression of MKK7 protein and were compared with vector-control ce… (full text at CIViC) PMID 40826108 · Alexandrou et al., 2025 · Open in CIViC	civic
MAP2K7 Loss-of-function	Fulvestrant + PalbociclibCombination	Predictive	D	Supports Resistance	4	submitted	EID13223 In ER-positive breast cancer models, MAP2K7 loss of function was associated with resistance to combined fulvestrant and palbociclib. Independent CRISPR/Cas9 MAP2K7 knockout in MCF-7 and T-47D cells re… (full text at CIViC) PMID 40826108 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.